Author Archives: admin


Stem Cell Clinic > Articles by: admin

Cell Harvesting Market Industry Trends and Forecast to 2025 | PerkinElmer Inc, Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical – Bandera County…

By Gene Therapy Clinics

Global Cell Harvesting Market,By Type (Manual Cell Harvesters and Automated Cell Harvesters), By Application (Biopharmaceutical Application, Stem Cell Research and other Applications), By End Users (Hospitals, Ambulatory Centers, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Market Analysis:Global Cell Harvesting Market

The Global Cell Harvesting Market is expected to reach USD 387.9 Million by 2025, from USD 196.9 Million in 2017 growing at a CAGR of 8.9% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Complete study compiled with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Sample @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cell-harvesting-market&skp

Market Definition:Global Cell Harvesting Market

This market report defines the market trends and forecast the upcoming opportunities and threats of the cell harvesting market in the next 8 years. Cell harvesting is extracting the cells either from bone marrow and peripheral blood cells and culturing the cells in the culture dish containing nutrient media. Cell harvesting is used in the cell therapy as well as in gene therapy. University of California developed a cure for bubble baby disease for new born babies by using the cell harvesting in stem cells and gene therapy. Moreover, Asterias developed the stem cell therapy to regain the upper body motor function. University of California, Irvine developed the stem cell therapy to destroy the breast cancer cells.. Now a days cell harvesting is also used in the animal research and development. Cell Harvesting is also used in may research labs for in-Vitro testing. In September 2016, Terumo BCT collaborated with Cognate Bioservices for developing the immunotherapies and other related products like cell therapy products. These innovations in the cell harvesting market is notably attributing towards its increasing demand at the global pace. Further, its demand is likely to gain momentum over the forecast period.

Major Market Drivers and Restraints:

Market Segmentation:Global Cell Harvesting Market

Competitive Analysis:Global Cell Harvesting Market

The global cell harvesting market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cell harvesting market for global, Europe, North America, Asia Pacific and South America.

Table Of Contents Is Available Here@https://www.databridgemarketresearch.com/toc/?dbmr=global-cell-harvesting-market&skp

Major Market competitors/players:Global Cell Harvesting Market

Some of the major players operating in the global cell harvesting market are PerkinElmer Inc, Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical, Argos Technologies, SP Industries, Teleflex Incorporated, Arthrex, Inc, Thomas Scientific, Brand GMBH, Brandel, Cox Scientific, Connectorate, Scinomix, Adstec.

Research Methodology:Global Cell Harvesting Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaseRequest an Analyst Callor can drop down your inquiry.

Demand Side Primary Contributors: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

The rest is here:
Cell Harvesting Market Industry Trends and Forecast to 2025 | PerkinElmer Inc, Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical - Bandera County...

Stempeutics partners with Global Consortium of cell therapy companies – BSI bureau

By Stem Cell Treatment

Stempeutics will test its stem cell product Stempeucel for Acute Respiratory Disease Syndrome (ARDS) caused by COVID-19 Pneumonia

Bengaluru based Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), announced that it has partnered with Global Consortium of cell therapy companies seeking European Commission Funding to Fight Against Corona! (FAC!).

Under this partnership, Stempeutics will export its stem cell product Stempeucel (subject to regulatory approvals) for treating critically ill COVID-19 patients with lung disease. First the product will be clinically tested and upon successful outcomes, it intends to export the product on a regular basis. In this connection it is signing up an alliance with Educell Ltd, Slovenia.

Stempeucel is an allogeneic, off the shelf, pooled mesenchymal stromal cells having antiinflammatory and immune-modulatory properties which prevents the over activation of the immune system. Stempeucel product exhibits a wide range of potent therapeutic properties.

The product exhibits potent immunomodulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the bodys immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs. Also, the growth factor, Angiopoietin-1 (Ang-1) is effective in reducing alveolar epithelium permeability in the lung. Hence it is envisaged, Stempeucel will reduce the fatal symptoms of COVID 19 induced pneumonia and its progression to ARDS.

BN Manohar, CEO of Stempeutics said, From the clinical data using Stempeucel in different clinical trialsin other indications it may be postulated that Stempeucel has the potential capability for treating COVID 19 infection. Together with the safety profile observed from DCGI approved clinical trials involving more than 350 patients injected with Stempeucel by different routes of injection, this therapy may help in mitigating the lung tissue damaging effects of COVID 19 infection.

Continued here:
Stempeutics partners with Global Consortium of cell therapy companies - BSI bureau

DNA Repair Gene-Related CHIP Is a Marker for Worse Outcomes in Patients With Lymphoma – Cancer Therapy Advisor

By Stem Cell Treatment

In contrast to findings from previously conducted retrospective single-centerstudies, results of a study of a large population-based cohort of patients withlymphoma undergoing autologous hematopoietic stem cell (HSC) harvesting showedno independent association between the general presence of clonal hematopoiesisof indeterminate origin (CHIP) and overall survival. These findings werepublished in Leukemia.1

In normal hematopoiesis, a single type of HSC accounts for only a verylow percentage of the overall HSCs present. However, in the case of CHIP, asingle HSC clone can expand to comprise 10% or more of the overall HSCpopulation.2 Specifically, CHIP has often been defined as thepresence of somatic mutations in HSCs at a variant gene frequency of 2% orhigher.3

Although CHIP can occur in individuals without a known hematologicmalignancy, previous retrospective studies of patients with cancer conducted atsingle centers with varying amounts of follow-up have shown worse clinicaloutcomes in those with CHIP compared with patients without this condition.

This large population-based study included data for 565 adult patientsfrom 5 independent national stem cell harvest registries from Denmark whounderwent autologous HSC harvesting between January 1, 2000, and July 1, 2012,followed by high-throughput DNA sequencing of HSC specimens.

Although this was a retrospective analysis, specimen collection andclinical follow-up were performed prospectively. The main aims of this studywas to evaluate the impact of CHIP on survival, as well as the tolerability ofautologous-HSC transplantation (ASCT).

Immediate HSCT was planned for 440 ofthese patients, and only this subgroup was included in the survival analysis. Thepercentages of lymphoma subtypes represented in this subgroup were as follows:diffuse large B-cell lymphoma (DLBCL; 37%), follicular lymphoma (8%), Hodgkinlymphoma (15%), mantle cell lymphoma (19%), peripheral T-cell lymphoma (PTCL;17%) and other lymphoma subtypes (4%).

In the patient subgroup for which immediateHSCT was planned, at least 1 CHIP mutation of any type or DNA repair pathway-relatedCHIP mutation was present in 112 (26%) and 40 patients (9.1%), respectively. Specifically,of the 143 total CHIP mutations identified, 48 (34%) encoded for a regulator ofDNA repair (ie, PPM1D, TP53, RAD21,BRCC3). Other types of CHIP mutations were mostcommonly identified in DNMT3Aand TET2.

At a median follow-up of 9.1 years, the overall group had a 15-yearoverall survival of 40.2%. Although OS was worse in the subgroup with CHIP,these patients were significantly older than thosewithout this condition (P <.0001).No significant difference in OS was found following multivariate analysesadjusting for age and aggressiveness of lymphoma subtype.

Incontrast, median OS was 2.2 years and 9.0 years in inthe subgroup of patients with CHIP mutations in DNA pathway-associated genescompared with those without these CHIP mutations. Multivariateanalyses showed significantly worse late but not early OS for those with these typesof CHIP mutations versus not (P =.00067). However, OS was not significantly different for thosewith common CHIP mutation in nonDNA repair-associated genes compared withthose without CHIP mutations.

Anotherinteresting finding of this study was that patients with CHIP mutations in DNArepair genes had a significantly higher risk of being admitted to an intensivecare unit compared with those without these mutations (P =.035 on multivariate analysis). Furthermore, this finding wasnot observed when the overall subgroups of those with and without any CHIPmutations were compared.

In their concluding remarks, the study authors commented that this information could aid [in] the identification of patients with lymphoma who are susceptible to adverse outcomes after ASCT.

References

More here:
DNA Repair Gene-Related CHIP Is a Marker for Worse Outcomes in Patients With Lymphoma - Cancer Therapy Advisor

Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma – Hematology Advisor

By Stem Cell Medical Center

While multiple myeloma (MM) remains an incurable disease, anexpanding range of treatment options in the past decade has led to greaterlong-term survival in this patient population, with a reported increase from 3years previously to at least 7 to 10 years currently.1 Additionalgains are expected as novel therapies for MM continue to emerge. In a reviewpublished in the International Journal of Hematology, Kenshi Suzuki, MD,PhD, director ofMyeloma andAmyloidosis Center at the Japanese RedCross Medical Center in Tokyo, examined the evolving state of treatment fortransplant-eligible MM patients.1 Key points from the article arehighlighted below.

Induction Regimen

Greater response rates and progression-free survival (PFS) rates have been observed with triplet regimens containing immunomodulatory drugs and proteasome inhibitors compared with doublet regimens. In an open-label phase 3 trial (525 patients) published in 2017 in the Lancet, bortezomib-lenalidomidedexamethasone (VRd) was linked to significant improvements in median PFS (43 vs 30 months; stratified hazard ratio [HR], 0.712; 96% CI, 0.56-0.906; one-sided P =.0018) and median overall survival (OS; 75 vs 64 months; HR, 0.709; 95% CI, 0.524-0.959; two-sided P =.025) compared to Rd.2

Among newly diagnosed patients, autologous stem celltransplantation (ASCT) following induction therapy is standard practice forthose who are physically fit and younger than 70 years.1 Highercomplete response (CR) rates (59% vs 48%; P =.03) and minimal residualdisease negativity (MRD) rates (79% vs 65%; P <.001) have been notedamong patients receiving ASCT compared with Vrd alone.

As stated in the review, high-dose melphalan followed byASCT has been linked with longer PFS and OS, as well as treatment-relatedmortality rates of less than 1%, and thus should be considered for all eligiblepatients.1 Study results indicate that early ASCT is associated withhigher rates of CR, MRD, and PFS compared with deferred ASCT. Furthermore,ASCT can be considered for salvage in fit patients if the interval between thefirst ASCT and relapse is 18months or more, Dr Suzuki wrote.

Post-Transplantation Consolidation/Maintenance Therapy

A 2018 study reported longer PFS (median 3.3vs2.6years, P <.0001) and OS (median 8.5 vs 6.3years; P<.0001) in patients who achieved CR within 1 year following diagnosis.3

To improve the outcome of ASCT, it is important toeradicate MM tumor cells through the synergistic immunological effects of ASCTand peri- and post-ASCT treatment, according to Dr Suzuki.1 In ourclinical practice, up-front ASCT is performed, followed by continuousmulti-consolidation/maintenance regimens until [MRD] is sustained for2years with DRd-Kd-EPd-Rd every 6months (b phase). Patients aresubsequently monitored for relapse or MRD resurgence before treatment is stopped.

AntiCD38monoclonal antibodies appear to have a synergistic effect with immunomodulatorydrugs, based on the upregulation of CD38 expression in MM cell lines bypomalidomide (Pom) and lenalidomide (Len). In the ongoing phase 3 MAIA trial,the risk of disease progression or death was 44% lower in newly diagnosed patientswith MM treated with daratumumab-Rd compared with Rd alone.4

In a phase 1b study of patients with relapsed or refractory MM (RRMM), single-agent isatuximab (Isa) demonstrated an overall response rate (ORR) of 24.3%, a median PFS of 3.7 months, and an OS of 18.6 months. Ongoing studies are investigating the use of Isa with pomalidomide/dexamethasone (Pd) in RRMM, and with VRd in newly diagnosed MM.1

Among other agents approved for RRMM, researchers found thatonce-weekly carfilzomib(K)-Rd (KRd) showed promising activity with an acceptable safety profilein patients with newly diagnosed MM and reduce[d] the burden on elderlypatients and those living far from hospitals.1 Elotuzumab (Elo) incombination with Pd (EPd) demonstrated an ORR of 53% vs 26% with Pd and wasfound to have a favorable safety profile. Patients with RRMM who receivedixazomib maintenance therapy after ASCT showed a 28% reduction in the risk ofprogression or death compared with placebo (median PFS, 26.5 vs21.3months).1

Other findings have shown prolonged PFS (median 11.2 vs7.1months, P <.0001) in patients with RRMM receiving bortezomib plus Pd (PVd) compared with Vd aftertreatment with 1 to 3 previous regimens including lenalidomide, and theefficacy and safety of oral Pom/CPA/Dex (PCd) in the first relapse followinglenalidomide and bortezomib has also been noted.1

Originally posted here:
Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma - Hematology Advisor

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2026 | Takeda Pharmaceutical Company Limited, Cytori…

By Stem Cell Medical Center

Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Applications (Eurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, Cardiovascular Diseases), By Product (Blood Pressure (BP) Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure (ICP) Monitoring Devices), By End User (Hospitals and Ambulatory Surgical Center), Country (Germany , France , United Kingdom , Italy, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) Industry Trends and Forecast to 2026

Market Analysis: EuropeAutologous Stem Cell and Non-Stem Cell Based Therapies Market

Europe autologous stem cell and non-stem cell based therapies market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed growing awareness of the therapeutic potential of stem cells in effective disease management and increased public-private investment in the development of stem cell therapies.

Avail 20% Discount on Buying This Report: Get a Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market&skp

Market Definition: EuropeAutologous Stem Cell and Non-Stem Cell Based Therapies Market

Autologous stem cell transplantation, the individuals own undivided cells or stem cells are collected and transplanted back to the person after intensive therapy. These therapies are performed using hematopoietic stem cells, in some cases, cardiac cells are used to correct the damage caused by heart attacks. Autologous and non-systemic stem cell therapies are used to treat different diseases, for example neurodegenerative diseases, cardiovascular diseases, cancer and autoimmune diseases, parasitic diseases.

Market Drivers

Market Restraints

Segmentation:EuropeAutologous Stem Cell and Non-Stem Cell Based Therapies Market

By Product Type

By Application

By End-User

By Country

Key Developments in the Market:

Competitive Analysis:

Europe Autologous Stem Cell and Non-Stem Cell Based therapies market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of autologous stem cell and non-stem cell based therapies market for Europe.

Table Of Contents Is Available [emailprotected]https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market&skp

Key Market Competitors:

Few of the major market competitors currently working in the europe autologous stem cell and non-stem cell based therapies market are Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Research Methodology:EuropeAutologous Stem Cell and Non-Stem Cell Based Therapies Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaserequest an analyst callor can drop down your enquiry.

The key research methodology used byDBMR researchteam is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

Customization of the Report:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See the original post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2026 | Takeda Pharmaceutical Company Limited, Cytori...

Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development – Business Wire

By Stem Cell Medical Center

VANCOUVER, British Columbia--(BUSINESS WIRE)--Products made by Vancouvers STEMCELL Technologies are now being used in over 30 COVID-19 studies worldwide. These studies are focusing on areas ranging from diagnostics and treatments to vaccine development and future prevention. STEMCELL is playing a crucial role in COVID-19 research by providing cutting-edge laboratory tools and reagents as well as through close collaborations with scientists. This will ultimately accelerate the pace of discovery and hopefully lead to a rapid resolution to the global pandemic.

At STEMCELL, we have a team of world-class scientists who have dedicated their careers to developing superior cell culture and cell isolation systems required to study devastating diseases, said Dr. Allen Eaves, STEMCELLs Founder, President, and CEO. It is always incredibly rewarding to see their hard work and expertise put to use. Every day were learning about new ways our customers are using our products to research solutions for the COVID-19 pandemic, and were actively working to support these researchers in any way we can.

STEMCELL is the global industry expert in developing systems for culturing human organoids, which are three-dimensional clusters of cells that closely resemble the biology of human organs. STEMCELL has partnered with an international team including Dr. Josef Penninger at the University of British Columbia, along with Nuria Montserrat in Spain, Drs. Haibo Zhang and Art Slutsky from Toronto, and Ali Mirazimis infectious biology team in Sweden. The group used STEMCELLs organoid systems in a study that examined how SARS-CoV-2 infects patients. Their findings, recently published in the top scientific journal Cell, provide insight into a potential treatment capable of stopping early infection of the novel coronavirus.

Human organoids enable us to better understand the pathology of this disease and to rapidly reach a therapeutic breakthrough. This work stems from an amazing collaboration among academic researchers and companies, including Dr. Ryan Conders gastrointestinal group at STEMCELL Technologies, who have all been working tirelessly day and night for weeks, said Dr. Penninger.

Life science researchers and clinical labs also depend on STEMCELLs specialized cell isolation tools and instruments to extract the white blood cells responsible for immune responses from blood samples. Dr. James Crowe at the Vanderbilt Vaccine Center in Nashville, Tennessee is using a custom version of STEMCELLs EasySep system to isolate specific immune cells from the blood of COVID-19 survivors. Their goal is to rapidly develop antibody treatments and vaccines. This research group has used the same system to identify potential treatments for other viruses, including Ebola, chikungunya, HIV, dengue, norovirus, and respiratory syncytial virus.

STEMCELL listened to us when we came to them asking for custom tools to isolate the specific immune cells were working with from COVID-19 patients, said Dr. Crowe. We were able to integrate the new products and protocols into our research. In turn, we hand information about these products back to STEMCELL so that they can make it available to other labs. Its been a productive collaboration.

STEMCELL recently reported that researchers at Chinas Centre for Disease Control (CDC) successfully used STEMCELLs lung cell culture product, PneumaCultTM, to grow human lung airway cells and quickly obtain the viruss gene sequence, drastically shortening the path to vaccine development. Additionally, an international team including long-time STEMCELL collaborator Dr. Franois Jean at the University of British Columbia, an expert in antiviral drug discovery and emerging human viruses, is using STEMCELLs lung tissue culture system in a recently-funded study to develop and evaluate candidate therapeutics for COVID-19.

Solving medical challenges requires experts in science and medicine to work together with efficiency and accuracy, says Dr. Eaves. STEMCELL is proud to be a crucial component of this network by providing innovative tools, services, and expertise needed by our colleagues in research labs and clinical settings globally.

In addition to supporting rapid and groundbreaking developments for COVID-19 research, STEMCELLs products have been used successfully to study many other devastating viruses. This includes the use of PneumaCult to study respiratory viruses such as various coronaviruses, parvovirus, rhinovirus, respiratory syncytial virus, and influenza. Scientists have also successfully modeled microcephaly caused by Zika virus and cytomegalovirus using STEMCELLs BrainPhys and other products for neuroscience research. Similarly, STEMCELLs IntestiCult was used to study viruses targeting the intestinal system, including enteric coronavirus and norovirus. Finally, STEMCELLs EasySep reagents and RoboSep instrument have been central to studies of the immune response to viruses including HIV, Ebola, and dengue viruses.

About STEMCELL Technologies

STEMCELL Technologies is Canadas largest biotechnology company, with over 1,500 employees and year-on-year growth of approximately 20% for the last 26 years. Based in Vancouver, STEMCELL supports life sciences research around the world with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources that are used by scientists advancing the stem cell, immunology, cancer, regenerative medicine, microbiology, and cellular therapy fields. Find more information at http://www.stemcell.com.

Read the rest here:
Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Business Wire

UC San Diego to Advance Stem Cell Therapies in New Space Station Lab – UC San Diego Health

By Stem Cell Clinic

A three-year, nearly $5 million award from NASA will allow researchers at the Sanford Stem Cell Clinical Center at UC San Diego Health, Sanford Consortium for Regenerative Medicine and their partners at Space Tango to develop a new integrated space stem cell orbital research laboratory within the International Space Station (ISS) and launch three collaborative research projects within it.

Stem cells self-renew, generating more stem cells, and specialize into tissue-specific cells, such as blood, brain and liver cells, making them ideal for biological studies far from Earths resources. The goal of the new effort is to leverage microgravity and these unique properties of stem cells to better understand how space flight affects the human body. The studies will also inform how aging, degenerative diseases, cancers and other conditions develop in a setting with increased exposure to ionizing radiation and pro-inflammatory factors. The findings from these studies may speed the development of new therapeutics for a broad array of degenerative diseases on Earth.

International Space Station (ISS) as seen from Space Shuttle Discovery in 2007. Credit: NASA

We envision that the next thriving ecosystem of commercial stem cell companies, the next nexus for biotechnology, could be created 250 miles overhead by the establishment of these capabilities on the ISS, said Catriona Jamieson, MD, PhD, co-principal investigator of the award and Koman Family Presidential Endowed Chair in Cancer Research, deputy director of Moores Cancer Center, director of the Sanford Stem Cell Clinical Center and director of the CIRM Alpha Stem Cell Clinic at UC San Diego Health.

The projects first flight to the ISS is planned for mid-2021. The ISS stem cell lab is expected to be fully operational and self-sustaining by 2025.

With hardware designed by Space Tango, a developer of fully automated, remote-controlled systems for research and manufacturing on orbit, initial projects in the new lab will include investigations of:

Blood cancers and immune reactivation syndromes, led by Jamieson, who is also a member of the Sanford Consortium for Regenerative Medicine, and Sheldon Morris, MD, MPH, clinical professor of family medicine and public health and infectious diseases at UC San Diego School of Medicine.

In whats known as the NASA Twins Study, investigators around the nation assessed identical twin astronauts Scott and Mark Kelly. Scott flew aboard the ISS for 342 days in 2015 and 2016, while his identical twin brother, Mark, remained on Earth. In a paper published in Science in early 2019, researchers, including UC San Diego School of Medicines Brinda Rana, PhD, described the many ways Scotts body differed from Marks due to his time spent in microgravity, including signs of pre-cancer.

Co-Principal Investigator Catriona Jamieson, MD, PhD.

In the new ISS lab, Jamieson and Morris will use stem cell-derived blood and immune cells to look for biomarkers tell-tale molecular changes as cancer develops and immune cells malfunction in microgravity. They will also work with experts in the Jacobs School of Engineering at UC San Diego and Space Tango to build special microscopes and bioreactors that fit the ISS lab space and transmit images to Earth in near real-time.

If we can find early predictors of cancer progression on the ISS, we are ideally positioned to rapidly translate them into clinical trials in our Sanford Stem Cell Clinical Center back on Earth, Jamieson said.

Brain stem cell regeneration and repair, led by Alysson R. Muotri, PhD, professor of pediatrics and cellular and molecular medicine and director of the Stem Cell Program at UC San Diego School of Medicine and a member of the Sanford Consortium for Regenerative Medicine, and Erik Viirre, MD, PhD, professor of neurosciences and director of the Arthur C. Clarke Center for Human Imagination.

Co-Principal Investigator Alysson Muotri, PhD, holding brain organoids in a laboratory dish at the Sanford Consortium for Regenerative Medicine. Credit: Erik Jepsen/UC San Diego Publications.

This project will build on a previous proof-of concept flight that sent a payload of stem cell-derived human brain organoids to the ISS in 2019. Brain organoids also called mini-brains are 3D cellular models that represent aspects of the human brain in the laboratory. Brain organoids help researchers track human development, unravel the molecular events that lead to disease and test new treatments.

Since their last trip to space, the UC San Diego team has significantly advanced the brain organoids levels of neural network activity electrical impulses that can be recorded by multi-electrode arrays.

All the research models we currently use to study aging in a laboratory dish rely on artificial things, such as increasing oxidative stress or manipulating genes associated with aging, said Muotri, who is also co-principal investigator on the award. Here, were taking a different approach to speed up the aging process and study how it plays a role in developmental diseases and neurodegenerative conditions such as Alzheimers.

Liver cell injury and repair, led by David A. Brenner, MD, vice chancellor of health sciences at UC San Diego, and Tatiana Kisseleva, MD, PhD, associate professor of surgery at UC San Diego School of Medicine.

On Earth, Brenner and Kisseleva study ailments of the liver, such as liver fibrosis and steatohepatitis, a type of fatty liver disease. Liver diseases can be caused by alcohol use, obesity, viral infection and a number of other factors. They are interested in determining the impact microgravity may have on liver function, which could provide insights into diseases on Earth, as well as potential effects during space travel. In the future, the team may test therapies for steatohepatitis in the new ISS lab, where microgravity mimics aging and can lead to liver cell injury.

These insights may allow us to develop new ways to stop the progression of liver disease and cirrhosis conditions that affect approximately 4.5 million people in the U.S., Brenner said.

Once the ISS stem cell lab is validated, the team said it will replicate the Earth-based Sanford Consortium for Regenerative Medicine, a collaboratory in La Jolla, Calif. that brings together experts from five research institutions: UC San Diego, Scripps Research, Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute and La Jolla Institute for Immunology.

Plans for the new ISS research lab and initial projects were made possible by an award from the NASA Research Opportunities for ISS Utilization. The UC San Diego team also credits the support of philanthropists T. Denny Sanford, Rebecca Moores Foundation and the Koman Family Foundation; their leadership, Pradeep Khosla, chancellor of UC San Diego, Patty Maysent, CEO of UC San Diego Health, Scott Lippman, MD, director of Moores Cancer Center at UC San Diego Health; and previous research and infrastructure funding from the National Institutes of Health, California Institute for Regenerative Medicine (CIRM), Pedal the Cause, and Leukemia & Lymphoma Society.

Disclosures: Muotri is a co-founder and has equity interest in TISMOO, a company dedicated to genetic analysis and brain organoid modeling, focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders with genetic origins. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict of interest policies.

See more here:
UC San Diego to Advance Stem Cell Therapies in New Space Station Lab - UC San Diego Health

Orgenesis partners with Belgium"s RevaTis to develop stem cells for therapeutic use – Proactive Investors USA & Canada

By Stem Cell Clinic

The two firms plan to leverage Orgenesiss autologous Cell and Gene Therapy Biotech Platform to produce muscle-derived mesenchymal stem cells (mdMSC) as a source of exosomes

Inc () is teaming up with regenerative medicine and cell therapy firm RevaTis on a new joint venture to produce certain stem cells for therapeutic use, it said Wednesday.

The two firms plan to leverage Orgenesiss autologous Cell and Gene Therapy (CGT) Biotech Platform to develop novel therapies and advance clinical trials.

Under the agreement, RevaTis and Orgenesis will use the formers patented technique to obtain muscle-derived mesenchymal stem cells (mdMSC) as a source of exosomes and various other cellular products.

Orgenesis and RevaTis are hoping to build on RevaTiss early success in animals to develop therapies and advance human trials using Orgenesiss expertise and Point-of-Care platform, which include automated systems, 3D printing and bioreactor technologies.

RevaTiss technologies are highly differentiated and ideally suited for Orgenesiss CGT Biotech Platform, Orgenesis CEO Vered Caplan told shareholders.

We believe that this exclusive partnership with RevaTis further validates the significant value proposition of the Orgenesis vertically integrated business model, Caplan said in a statement Wednesday.

This model allows us to streamline the entire process of therapeutic development and delivery of cell therapies within the patient care setting through our Cell & Gene Biotech Platform.

RevaTis also has existing partnerships with research institutions in the US, the Middle East and India that will be highly complementary to Orgenesiss POCare Network, according to Caplan. We look forward to utilizing the Orgenesis Cell & Gene Biotech Platform with a goal to lower the costs and accelerate the timeline of bringing these innovative therapies through the clinic and potentially into commercialization.

RevaTis CEO Didier Serteyn said the firm was delighted to partner with Orgenesis on the new venture.

We selected Orgenesis as a result of their extensive experience in the field of autologous cell therapies, including technical, clinical and regulatory expertise, Serteyn said in a statement. We expect that this will be valuable as we aim to advance our platform through commercialization.

Germantown, Maryland-based Orgenesis is a vertically integrated biopharmaceutical company with expertise in developing advanced cell therapies and manufacturing.

Shares of Orgenesis jumped 5.8% on Wednesday to reach $4.40 by midday.

Contact Angela at [emailprotected]

Follow her on Twitter @AHarmantas

Follow this link:
Orgenesis partners with Belgium"s RevaTis to develop stem cells for therapeutic use - Proactive Investors USA & Canada

Induced Pluripotent Stem Cells Market Key Players, Size, Share, Growth, Trends, Analysis And Forecast 2025 – Science In Me

By Induced Pluripotent Stem Cells

A report added to the rich database of Qurate Business Intelligence, titled Global Induced Pluripotent Stem Cells Market Size, Status and Forecast 2025, provides a 360-degree overview of the worldwide market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the data reliable in context to particular time period and industry.This report is highly informative document with inclusion of comprehensive market data associated with the significant elements and subdivision of the Global Induced Pluripotent Stem Cells Market that may impact the growth scenarios of the industry. The report may commendably help trades and decision makers to address the challenges and to gain benefits from highly competitive Global Induced Pluripotent Stem Cells Market

Get Free Sample Copy of This [emailprotected]https://www.qurateresearch.com/report/sample/ICT/global-induced-pluripotent-stem-cells-market/QBI-MMR-ICT-592258

A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.

The major players profiled in this report include:

Fujifilm Holding Corporation (CDI)NcardiaSumitomo Dainippon PharmaAstellas Pharma IncFate Therapeutics, IncPluricell BiotechCell Inspire BiotechnologyReproCELL

Major types in global Induced Pluripotent Stem Cells market includes:Human iPSCsMouse iPSCs

Major application in global Induced Pluripotent Stem Cells market includes:Academic ResearchDrug Development and DiscoveryToxicity ScreeningRegenerative MedicineOthers

Global Induced Pluripotent Stem Cells Market is research report of comprehensive nature which entails information in relation with major regional markets, current scenarios. This includes key regional areas such as North America, Europe, Asia-Pacific, etc. and the foremost countries such as United States, Germany, United Kingdom, Japan, South Korea and China.

The Global Induced Pluripotent Stem Cells Market report attempts to build familiarity of the market through sharing basic information associated with the aspects such as definitions, classifications, applications and market overview, product specifications, manufacturing processes, cost structures, raw materials and more. Furthermore, it strives to analyze the crucial regional markets, including the product price, profit, capacity, production, supply, demand and market growth rate. It also discusses forecast for the same. The report concludes with new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Do You Have Any Query? Ask to Our Industry [emailprotected]https://www.qurateresearch.com/report/enquiry/ICT/global-induced-pluripotent-stem-cells-market/QBI-MMR-ICT-592258

In addition, this report identifies pin-point analysis of competitive dashboard and helps readers to develop competitive edge over others. It delivers a noteworthy data and insights associated with factors driving or preventing the growth of the market. It brings a nine-year forecast evaluated on the basis of how the market is expected to perform.

It assists readers in understanding the key product sections and their future. Its counsels in taking well-versed business decisions by giving complete intuitions of the market and by forming a comprehensive analysis of market subdivisions. To sum up, it also provides confident graphics and personalized SWOT analysis of foremost market subdivisions.This statistical surveying report presents comprehensive assessment of the global market for Induced Pluripotent Stem Cells, discussing several market verticals such as the production capacity, product pricing, the dynamics of demand and supply, sales volume, revenue, growth rate and more.

Buy Complete [emailprotected]https://www.qurateresearch.com/report/buy/ICT/global-induced-pluripotent-stem-cells-market/QBI-MMR-ICT-592258

Table of Content:

Global Global Induced Pluripotent Stem Cells Market Research Report 2020-2025

Chapter 1: Industry Overview

Chapter 2: Induced Pluripotent Stem Cells International and China Market Analysis

Chapter 3: Environment Analysis of Induced Pluripotent Stem Cells

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Induced Pluripotent Stem Cells Revenue Market Status.

Chapter 7: Analysis of Induced Pluripotent Stem Cells Industry Key Manufacturers

Chapter 8: Sales Price and Gross Margin Analysis

Chapter 9: Marketing Trader or Distributor Analysis of Induced Pluripotent Stem Cells Market

Chapter 10: Development Trend of Induced Pluripotent Stem Cells Industry 2020-2025

Chapter 11: Industry Chain Suppliers of Induced Pluripotent Stem Cells with Contact Information

Chapter 12: New Project Investment Feasibility Analysis of Induced Pluripotent Stem Cells

Chapter 13: Conclusion of the Global Induced Pluripotent Stem Cells Market Research Report

Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Qurate Business Intelligence delivers unique Market research solutions to its customers and help them to get equipped with refined information and Market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Read the rest here:
Induced Pluripotent Stem Cells Market Key Players, Size, Share, Growth, Trends, Analysis And Forecast 2025 - Science In Me

Induced Pluripotent Stem Cells (iPSCs) Market in 2020: Industry Overview on Global Size, Share, Future Trends, Segmentation, Demands, and Top Players…

By Induced Pluripotent Stem Cells

The Induced Pluripotent Stem Cells (iPSCs) Market Report is an outstanding offering of critical dynamics, geographical growth, competition, and other relevant aspects of the global Induced Pluripotent Stem Cells (iPSCs) market. It provides accurate market figures and statistics including CAGR, volume, revenue, consumption, market share, production, price, and gross margins. Every local market studied in this report is accurately analyzed to explore key opportunities and business prospects they are expected to offer in the near future. Global Induced Pluripotent Stem Cells (iPSCs) market report assists industry enthusiasts including investors and decision-makers to make confident capital investments, develop strategies, optimize their business portfolio, innovate successfully and perform safely and sustainably.

This Report Covers Leading Companies Associated in Worldwide Induced Pluripotent Stem Cells (iPSCs) Market:

Fujifilm Holding Corporation (CDI),Ncardia,Sumitomo Dainippon Pharma,Astellas Pharma Inc,Fate Therapeutics, Inc,Pluricell Biotech,Cell Inspire Biotechnology,ReproCELL

Get Free Sample PDF Copy (including full TOC, Tables, and Figures) of Induced Pluripotent Stem Cells (iPSCs) Market Report @ https://www.esherpamarketreports.com/request-sample/es-379889/

Key Businesses Segmentation of Induced Pluripotent Stem Cells (iPSCs) Market:

Global Induced Pluripotent Stem Cells (iPSCs) Market Segment by Type, covers

Global Induced Pluripotent Stem Cells (iPSCs) Market Segment by Applications, can be divided into

Induced Pluripotent Stem Cells (iPSCs) Market Report Covers Following Questions

What are the weaknesses and strengths of the key vendors?What are the key outcomes of the five forces analysis of the Global Induced Pluripotent Stem Cells (iPSCs) market?What are the various threats and opportunities faced by the dealers in the Global Induced Pluripotent Stem Cells (iPSCs) market?Who are the leading key players and what are their key business strategies in the Global Induced Pluripotent Stem Cells (iPSCs) market?

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-379889

Table of Contents1 Induced Pluripotent Stem Cells (iPSCs) Market Overview1.1 Product Overview and Scope of Induced Pluripotent Stem Cells (iPSCs)1.2 Induced Pluripotent Stem Cells (iPSCs) Segment by Type1.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Production Growth Rate Comparison by Type 2020 VS 20261.2.2 Compact Type Induced Pluripotent Stem Cells (iPSCs)1.2.3 Standard Type Induced Pluripotent Stem Cells (iPSCs)1.3 Induced Pluripotent Stem Cells (iPSCs) Segment by Application1.3.1 Induced Pluripotent Stem Cells (iPSCs) Consumption Comparison by Application: 2020 VS 20261.4 Global Induced Pluripotent Stem Cells (iPSCs) Market by Region1.4.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size Estimates and Forecasts by Region: 2020 VS 20261.4.2 North America Estimates and Forecasts (2015-2026)1.4.3 Europe Estimates and Forecasts (2015-2026)1.4.4 China Estimates and Forecasts (2015-2026)1.4.5 Japan Estimates and Forecasts (2015-2026)1.5 Global Induced Pluripotent Stem Cells (iPSCs) Growth Prospects1.5.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Estimates and Forecasts (2015-2026)1.5.2 Global Induced Pluripotent Stem Cells (iPSCs) Production Capacity Estimates and Forecasts (2015-2026)1.5.3 Global Induced Pluripotent Stem Cells (iPSCs) Production Estimates and Forecasts (2015-2026)2 Market Competition by Manufacturers2.1 Global Induced Pluripotent Stem Cells (iPSCs) Production Capacity Market Share by Manufacturers (2015-2020)2.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Manufacturers (2015-2020)2.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.4 Global Induced Pluripotent Stem Cells (iPSCs) Average Price by Manufacturers (2015-2020)2.5 Manufacturers Induced Pluripotent Stem Cells (iPSCs) Production Sites, Area Served, Product Types2.6 Induced Pluripotent Stem Cells (iPSCs) Market Competitive Situation and Trends2.6.1 Induced Pluripotent Stem Cells (iPSCs) Market Concentration Rate2.6.2 Global Top 3 and Top 5 Players Market Share by Revenue2.6.3 Mergers & Acquisitions, Expansion3 Production Capacity by Region3.1 Global Production Capacity of Induced Pluripotent Stem Cells (iPSCs) Market Share by Regions (2015-2020)3.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Regions (2015-2020)3.3 Global Induced Pluripotent Stem Cells (iPSCs) Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.4 North America Induced Pluripotent Stem Cells (iPSCs) Production3.4.1 North America Induced Pluripotent Stem Cells (iPSCs) Production Growth Rate (2015-2020)3.4.2 North America Induced Pluripotent Stem Cells (iPSCs) Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.5 Europe Induced Pluripotent Stem Cells (iPSCs) Production3.5.1 Europe Induced Pluripotent Stem Cells (iPSCs) Production Growth Rate (2015-2020)3.5.2 Europe Induced Pluripotent Stem Cells (iPSCs) Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.6 China Induced Pluripotent Stem Cells (iPSCs) Production3.6.1 China Induced Pluripotent Stem Cells (iPSCs) Production Growth Rate (2015-2020)3.6.2 China Induced Pluripotent Stem Cells (iPSCs) Production Capacity, Revenue, Price and Gross Margin (2015-2020)3.7 Japan Induced Pluripotent Stem Cells (iPSCs) Production3.7.1 Japan Induced Pluripotent Stem Cells (iPSCs) Production Growth Rate (2015-2020)3.7.2 Japan Induced Pluripotent Stem Cells (iPSCs) Production Capacity, Revenue, Price and Gross Margin (2015-2020)4 Global Induced Pluripotent Stem Cells (iPSCs) Consumption by Regions4.1 Global Induced Pluripotent Stem Cells (iPSCs) Consumption by Regions4.1.1 Global Induced Pluripotent Stem Cells (iPSCs) Consumption by Region4.1.2 Global Induced Pluripotent Stem Cells (iPSCs) Consumption Market Share by Region5 Production, Revenue, Price Trend by Type5.1 Global Induced Pluripotent Stem Cells (iPSCs) Production Market Share by Type (2015-2020)5.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2015-2020)5.3 Global Induced Pluripotent Stem Cells (iPSCs) Price by Type (2015-2020)5.4 Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End6 Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis by Application. And More

Click Here For Detailed Table Of Contents

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-379889/

Contact Us:

Name: Jason George

Email: [emailprotected]

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Read the original post:
Induced Pluripotent Stem Cells (iPSCs) Market in 2020: Industry Overview on Global Size, Share, Future Trends, Segmentation, Demands, and Top Players...

→←